Clinical Trials Browser

Phase 3 × Unknown × olverembatinib × Clear all

NCT05311943 2022-07-29

Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.

Phase 3 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase